An interventional study of Febuxostat and allopurinol in Hyperuricemia and Renal Insufficiency, Chronic, sponsored by Nishtar Medical University. Active, not recruiting at 1 site in Pakistan. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Nishtar Medical University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing febuxostat in Hyperuricemia — 2 open to participants now, 4 under way, none of them phase 3. Febuxostat · Hyperuricemia.
Among the 26 studies testing febuxostat in Hyperuricemia, this one is the 19th largest by enrollment, is one of 3 that started in 2026, is one of 6 with no phase, and was the 26th registered.
240 studies on the registry are indexed under Hyperuricemia; 44 are open to participants now.
Browse Hyperuricemia studies →2 of the 26 studies testing febuxostat in Hyperuricemia are open now, in 1 country. Recruiting first, the newest first:
Jiangsu HengRui Medicine Co., Ltd. · Sites in China
Ages 18–75
Haiphong University of Medicine and Pharmacy
Healthy volunteers
By country, each count listing its studies:
Febuxostat: first FDA approval 2009 (ULORIC), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 30 Hyperuricemia studies recruiting now, 9 (30%) set no upper age limit and 13 (43%) stop at 75 or younger; 1 takes children under 18; 6 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 66 is close to the median of 68 across 193 interventional studies indexed under Hyperuricemia.
Median enrollment 111 across the 26 interventional studies. Of the 15 that completed or were terminated, 7 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 26 have an industry lead sponsor. The 10 most frequent:
Nishtar Medical University is the lead sponsor of 30 studies on the registry; 9 are open to participants now.
Nishtar Medical University has 1 study filed under Hyperuricemia — fewer than ten, so there is no comparison to draw.
2 of the studies testing febuxostat in Hyperuricemia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07369622Haiphong University of Medicine and PharmacyHLA-B*58:01-Guided Therapy for Gout: Effectiveness, Safety, and Cost-Effectiveness | 2027-06-20 |
| NCT07362355Jiangsu HengRui Medicine Co., Ltd.The Efficacy and Safety of SHR4640 Tablet Combined With 40 mg Febuxostat Tablets in the Treatment of Primary Gout and Hyperuricemia | 2027-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 26 studies testing febuxostat in Hyperuricemia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This randomized study was designed to compare how well allopurinol and febuxostat lowered blood uric acid in adults with chronic kidney disease and high uric acid levels. It was planned to include 66 participants, aged 18 to 65 years, with stage 3 to 5 chronic kidney disease. Participants were to be assigned to receive either febuxostat 40 mg daily or allopurinol at a dose adjusted for their level of kidney function. Treatment was planned for eight weeks, with follow-up visits at weeks 4 and 8.
The researchers hypothesized that the two medicines would differ in their effects after eight weeks. The main measure was the proportion of participants whose uric acid level reached below 6.0 mg/dL. Changes in uric acid levels and estimated kidney function were also to be compared.
Inclusion Criteria:
Exclusion Criteria:
Exclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants assigned to this group were to receive febuxostat 40 mg orally once daily for 8 weeks.
Drug: Febuxostat
Participants assigned to this group were to receive allopurinol orally for 8 weeks, with the starting dose determined by chronic kidney disease stage.
Drug: allopurinol
40 mg orally once daily for 8 weeks.
Stage 3: 100 mg once daily; stage 4: 50 mg once daily; stage 5: 50 mg once daily or every other day, according to the study protocol.
Percentage of Participants Achieving Serum Uric Acid Below 6.0 mg/dL
The percentage of participants in each treatment group whose serum uric acid level was below 6.0 mg/dL at the 8-week assessment.
Time frame: 8 weeks after treatment initiation
Change in Serum Uric Acid From Baseline to 8 Weeks
The mean change in serum uric acid in each treatment group, calculated as the 8-week value minus the baseline value and expressed in mg/dL.
Time frame: Baseline and 8 weeks after treatment initiation
Change in Estimated Glomerular Filtration Rate From Baseline to 8 Weeks
The mean change in estimated glomerular filtration rate in each treatment group, calculated as the 8-week value minus the baseline value and expressed in mL/min/1.73 m².
Time frame: Baseline and 8 weeks after treatment initiation
Started May 2026 (actual). Primary completion is estimated for Nov 2026, 5 months after the start.
Of 26 interventional studies with no phase under Hyperuricemia, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 34. This study's planned 5 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Febuxostat
Nishtar Medical University